GT Biopharma Advances Immunotherapy with GTB-3650 in Phase 1 Clinical Trial for Blood Cancers

GT Biopharma Pushes Forward in Immunotherapy with GTB-3650

GT Biopharma, Inc. is making significant advancements in the field of cancer immunotherapy with its investigational drug GTB-3650. The company has recently completed a safety review for the third dosing group (Cohort 3) in its Phase 1 clinical trial, which targets patients with relapsed or refractory blood cancers, particularly acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The review shows no safety or tolerability issues, allowing the company to progress to the fourth cohort, where patients will receive a dose of 10μg/kg/day. Patient screening is currently underway, and dosing is expected to commence shortly.

The Phase 1 study aims to evaluate the safety and efficacy of GTB-3650, which utilizes a unique mechanism to enhance the body’s natural killer (NK) cells, essential in identifying and destroying malignant cells. The treatment regimen consists of continuous infusions over two weeks, followed by a two-week rest period, which may be repeated for up to four months depending on the patients' responses. So far, six patients have been treated in the initial cohorts, with all demonstrating tolerability at escalating doses. The company notes promising trends in immunological biomarkers among these patients, indicating that the fourth cohort's dosing could result in significant clinical benefits.

This encouraging progress occurs against the backdrop of the FDA's recent approval of the first once-daily menin inhibitor for relapsed NPM1-mutated AML, underscoring a growing recognition of innovative and targeted therapies for blood cancers. As GT Biopharma navigates this evolving landscape, the company is poised to provide a comprehensive update on its clinical trials in the first quarter of 2026, aiming to address some of the most challenging cancer types through its cutting-edge immunotherapy approaches.

In addition to its clinical advancements, GT Biopharma’s strategic focus aligns well with industry trends emphasizing personalized medicine in oncology. The successful completion of safety reviews and the ongoing clinical trials signal the company’s commitment to developing effective treatments for patients with limited options. With increasing interest in immunotherapy, GTB-3650 could become a significant player in the competitive landscape of cancer therapeutics.